J.H. Whitney Equity Partners VII, LLC sold $169.6M of AVAH (indirect holdings)

J.H. Whitney Equity Partners VII, LLC sold 14,746,077 indirectly-held shares of Aveanna Healthcare Holdings, Inc. (AVAH) at $11.50 ($169.58M total) across 4 trades over 2026-08-20 to 2026-08-21.

Original reporting
SEC EDGAR · J.H. Whitney Equity Partners VII, LLC
Published Aug 24, 2026, 10:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 10:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVAH
Bearish
high confidence
Mentioned
$AVAH
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVAHBearishMed
01

Why it matters

The transaction reduces insider ownership and may be interpreted as reduced confidence, potentially prompting short sellers.

02

Market read

Significant insider sell provides fresh material for traders to assess AVAH's near‑term price direction.

03

What to watch

Potential upcoming earnings or strategic moves not disclosed yet.

Relevance 8/10Novelty 8/10Timing: today

Background

Form 4 filing by a 10% owner disclosing a $169.6M open‑market sale of AVAH shares.

Company-level read

Ticker impact

$AVAHBearishHigh confidence
Context

J.H. Whitney Equity Partners VII sold $169.6M of AVAH shares, reducing its stake to 12.3M shares.

Expected impact

Potential short-term downside pressure.

Evidence & confidence

The sale represents a 14.7M share reduction at $11.50 per share, a material transaction for a 10% owner.

Market effects

May weigh on healthcare services sector sentiment as a large insider exits.

Limited to US markets where AVAH trades.

Minimal global impact beyond AVAH investors.

Counterpoint

The sale could be a portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Aveanna Healthcare Holdings, Inc.

    Issuer of the shares sold.

  • J.H. Whitney Equity Partners VII, LLC

    10% owner executing the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.